Investigation of the effects and mechanisms of action of different wavelengths of ultraviolet B (UVB) radiation in the treatment of psoriasis

ISRCTN ISRCTN43688684
DOI https://doi.org/10.1186/ISRCTN43688684
Secondary identifying numbers 5623; 079504
Submission date
12/05/2010
Registration date
12/05/2010
Last edited
13/12/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Skin and Connective Tissue Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Sophie Weatherhead
Scientific

Newcastle University
Dermatology
2nd Floor William Leech Building
Medical School
Newcastle
NE2 4HH
United Kingdom

Study information

Study designSingle centre non-randomised interventional treatment trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Other
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleInvestigation of the effects and mechanisms of action of different wavelengths of ultraviolet B (UVB) radiation in the treatment of psoriasis: a single centre non-randomised treatment trial
Study acronymMECH-UVB-PSOR
Study objectivesTo test the hypothesis that keratinocyte apoptosis is an important mechanism of action of ultraviolet B (UVB) phototherapy in the clearance of psoriasis, and to investigate the correlation between effectiveness of different wavelengths of UV and apoptotic response in the clearance of psoriasis.
Ethics approval(s)County Durham and Tees Valley (1) REC, ref: 06/Q1003/78
Health condition(s) or problem(s) studiedTopic: Skin; Subtopic: Skin (all Subtopics); Disease: Dermatology
InterventionCompare the apoptotic effect of different wavelengths of UVB in psoriatic epidermis in vivo.
Intervention typeOther
Primary outcome measureWhether the number of apoptotic cells seen within the epidermis is sufficient to allow plaque remodelling. Measured up to 48 hours (4 hours, 8 hours, 12 hours,15 hours, 18 hours, 24 hours, and 48 hours).
Secondary outcome measures1. Effect of skin type
2. UV dose
3. Age and gender

Measured up to 48 hours (4 hours, 8 hours, 12 hours,15 hours, 18 hours, 24 hours, and 48 hours).
Overall study start date01/10/2006
Completion date30/04/2010

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participantsPlanned sample size: 121
Key inclusion criteria1. Aged 18 years and over, with no sex specific criteria
2. All patients who are prescribed routine UVB (TL01) for their psoriasis at our centre
3. Give informed consent to participate
Key exclusion criteria1. Aged under 18 years
2. Systemic immunosupression within 3 months
3. UVB exposure to lower back within 3 months of recruitment
4. Topical treatments other than emollients for 2 weeks
Date of first enrolment01/10/2006
Date of final enrolment30/04/2010

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Newcastle University
Newcastle
NE2 4HH
United Kingdom

Sponsor information

Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)
Hospital/treatment centre

Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
England
United Kingdom

Website http://www.newcastle-hospitals.org.uk/
ROR logo "ROR" https://ror.org/05p40t847

Funders

Funder type

Charity

The Wellcome Trust (UK) (grant ref: 079504)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Editorial Notes

13/12/2019: No publications found, verifying study status with principal investigator.
09/05/2016: No publications found, verifying study status with principal investigator.